Digital Phablet

Tag: Ozempic

  • Rare Vision Loss Disease Tied to Common Diabetes Medication

    Rare Vision Loss Disease Tied to Common Diabetes Medication

    A popular medication for diabetes management is now under scrutiny after new research indicates it may increase the risk of a rare but serious eye condition that can result in permanent vision loss.

    Researchers from the University of Southern Denmark conducted two extensive studies examining the safety profile of Ozempic, a widely prescribed drug for type 2 diabetes. This medication has surged in popularity recently because it not only helps regulate blood sugar levels but also supports weight reduction. Nonetheless, recent findings highlight a potential unexpected side effect related to eye health.

    The concern centers around non-arteritic anterior ischemic optic neuropathy (NAION), a condition where blood flow to the optic nerve suddenly diminishes. The optic nerve is crucial for transmitting visual signals to the brain. When it sustains damage, it can lead to rapid vision loss, which might be irreversible.

    Though NAION is uncommon, its impact can be devastating. Individuals affected may experience vision loss in one eye, and in some cases, the other eye might become involved later on. Because even a slight increase in risk carries serious implications, health professionals and researchers are paying close attention.

    This issue was initially brought up by a smaller U.S. study that suggested Ozempic could more than double the likelihood of developing NAION. The newer studies from Denmark bolster this evidence thanks to larger patient populations and the utilization of national health data.

    One of the Danish studies analyzed medical records from over 424,000 individuals with type 2 diabetes, including more than 106,000 who used Ozempic. The results indicated that patients on Ozempic had approximately twice the risk of developing NAION when compared to those on other diabetes therapies.

    The researchers also observed a trend over time. Before Ozempic’s widespread adoption in Denmark around 2018, annual NAION cases ranged from 60 to 70. Recently, this number rose to roughly 150 cases per year, predominantly among those with type 2 diabetes.

    A second study focused on new users of Ozempic, comparing their health outcomes with those starting other diabetes treatments in Denmark and Norway. This approach allowed for a more precise comparison between similar groups. The findings were consistent, again showing that Ozempic users faced about double the risk of NAION.

    While these findings may seem alarming, it’s important to emphasize that the overall risk remains low. NAION remains a rare condition, and most patients taking Ozempic will never experience it. For many, the benefits of controlling blood sugar and reducing the risk of complications like cardiovascular and renal issues outweigh the potential risks.

    Experts advise that treatment decisions should always weigh both benefits and harms. Managing type 2 diabetes effectively is critical because high blood sugar can contribute to serious issues such as heart disease, kidney failure, and nerve damage.

    Healthcare providers also note that alternative medications are available, many of which can offer similar benefits in blood sugar control and organ protection. For patients with existing vision problems or higher susceptibility to eye issues, discussing these options with a healthcare professional might be advisable.

    Patients currently on Ozempic should not discontinue use without medical guidance. Abruptly stopping treatment may lead to poor blood sugar regulation and other health complications. Instead, anyone concerned about side effects should consult their doctor, particularly if they notice sudden changes in vision, such as blurriness or dark spots.

    The findings from these studies have been shared with health authorities and may influence future guidelines on Ozempic’s safe use. Researchers hope this information will facilitate more individualized treatment plans, enabling doctors to select the most appropriate medication based on each patient’s unique risks.

    The studies were published in the International Journal of Retina and Vitreous and are also available as preprints on medRxiv. While more research is necessary, these results underscore the importance of ongoing monitoring for side effects and continuous evaluation of widely used medications.

    Overall, the message isn’t to avoid treatment but to remain informed. Every medication offers benefits and potential risks. Patients who understand these factors and maintain open communication with their healthcare providers can make the safest choices for their health.

    For those interested in diabetes-related nutrition, recent studies suggest that flaxseed oil may offer more benefits than fish oil for people with diabetes, and green tea could help reduce mortality risk. Additionally, research indicates that blueberries significantly benefit individuals with metabolic syndrome, and vitamin D supplementation might improve blood pressure in diabetics.

    Copyright © 2026 Knowridge Science Report. All rights reserved.

  • Can Ozempic Aid Brain Metastasis in Cancer Patients?

    Can Ozempic Aid Brain Metastasis in Cancer Patients?

    Weight-loss injections, widely known for their role in helping people shed pounds, could also have the potential to extend the lives of some patients with advanced cancer that has metastasized to the brain, according to new research. These medications belong to a class called GLP-1 receptor agonists, which include drugs like Wegovy and Ozempic. Originally created to manage type 2 diabetes, they’ve garnered global attention in recent years due to their notable weight-loss effects.

    This recent study doesn’t claim these injections directly treat cancer, but suggests a more subtle benefit: they might help some seriously ill patients live longer. The research specifically investigates the impact on brain metastases, which occur when cancer cells travel from organs like the lungs, breasts, or skin to form tumors in the brain. This condition often indicates a late, more dangerous stage of cancer.

    Many individuals with brain metastases also have type 2 diabetes, complicating their condition. High blood sugar levels can trigger ongoing inflammation, damage blood vessels, and weaken the body’s ability to recover. In clinical practice, steroids are frequently prescribed to reduce brain swelling and manage symptoms, but they tend to raise blood sugar, complicating diabetes control.

    This has prompted researchers to consider whether GLP-1 receptor drugs could provide additional benefits beyond blood sugar regulation. Laboratory studies indicate these drugs may protect brain cells, lessen inflammation, and support healthy blood flow within the brain. However, real-world clinical data on how patients with both diabetes and brain metastases fare when taking these medications has been limited—until now.

    The new study, published in JAMA Network Open, utilized a large database of anonymized health records from 151 hospitals worldwide, focusing on adults with cancer, type 2 diabetes, and brain metastases, between 2018 and 2024. Researchers examined whether these patients had been prescribed GLP-1 drugs—such as semaglutide, dulaglutide, liraglutide, or tirzepatide—around the time their diagnoses were made.

    To ensure fair comparisons, patients treated with GLP-1 medications were matched with similar individuals who had not received them, considering factors like age, gender, type of cancer, other health conditions, and treatments including chemotherapy, radiation, and steroids. While no method is perfect, matching helps minimize bias and makes the results more reliable.

    Out of more than 19,000 patients analyzed, 866 had been treated with a GLP-1 drug, while over 11,000 had not. After pairing similar patients, the study focused on two groups of 850 individuals each, tracking survival over three years following the diagnosis of brain metastases.

    Results showed that those taking GLP-1 medications were significantly less likely to die during that period—about 37% less likely compared to those not on these drugs. This survival benefit was consistent across various cancer types, including lung, breast, and melanoma, and was observed across different drugs within the GLP-1 class.

    Further comparison with other recent diabetes treatments, like SGLT2 inhibitors and DPP-4 inhibitors, revealed that GLP-1 drugs still offered a survival advantage. This suggests that the benefit isn’t solely due to better blood sugar control but may involve specific actions of GLP-1 signaling.

    However, the researchers emphasized a key limitation: the study was retrospective, based on existing medical records rather than controlled clinical trials. To definitively establish cause and effect, randomized studies are necessary, where patients are assigned treatments in a controlled manner and followed prospectively.

    How might these medications help patients with brain metastases? One possibility is that they indirectly improve overall health by better managing diabetes—leading to weight loss, improved cardiovascular health, and enhanced ability to tolerate treatments. There could also be direct effects in the brain: GLP-1 receptors exist in brain tissue and are involved in controlling inflammation, protecting nerve cells, and maintaining the blood-brain barrier—a protective layer that blocks harmful substances from entering the brain.

    Animal studies support this idea, showing activation of GLP-1 receptors can reduce brain cell damage and support their proper functioning. This might make the brain more resilient against metastatic tumors or create an environment less conducive to cancer growth. The clinical findings align with these hypotheses, though the precise mechanisms remain to be fully understood.

    It’s important for patients and their families to recognize what this research means—and what it doesn’t. The study does not suggest that individuals with brain metastases should start GLP-1 drugs immediately, nor that these medications replace standard cancer treatments such as radiation, surgery, targeted therapies, or immunotherapy. The observed benefits were specific to people who already had type 2 diabetes, and these drugs can cause side effects like nausea and vomiting, with rare but serious risks.

    Those considering these medications should consult with their healthcare providers for personalized advice, rather than making decisions based solely on this recent research. Still, these findings open an exciting avenue for future studies exploring the link between metabolism, brain health, and cancer survival. If ongoing research confirms that GLP-1 drugs truly boost survival rates in patients with brain metastases and diabetes, they could eventually become part of supportive care approaches for this challenging complication.

  • Kuwaiti Influencer Hospitalized Following Mounjaro Injection

    Kuwaiti Influencer Hospitalized Following Mounjaro Injection

    Mounjaro

    ALBAWABA – Recently, Kuwaiti social media influencer Jamal Al Najadah found herself hospitalized in China after administering a Mounjaro injection without consulting a doctor, resulting in severe health complications.

    Mounjaro, much like Ozempic, is typically prescribed to individuals with Type 2 diabetes to help reduce blood sugar levels and promote weight loss. Although it’s crucial to seek medical guidance, these medications have gained fame among celebrities seeking rapid weight loss solutions.

    Many individuals, including public figures, view these injections as a simpler, quicker alternative to traditional weight management methods such as proper nutrition and exercise.

    In a recent social media post, Al Najadah shared a cautionary tale for her followers. She disclosed that her hospitalization stemmed from serious internal bleeding and stomach ulcers after using Mounjaro.

    Kuwaiti Influencer Hospitalized Following Mounjaro Injection

    Al Najadah explained that her health problems arose after she self-administered the Mounjaro injection. In a viral video, she remarked, "I acted as my own doctor and ended up with stomach bleeding."

    She clarified that while the medication can be safe when prescribed by a healthcare professional, it poses risks if misused without medical supervision. Followers commended Al Najadah for her transparency and forthrightness on this issue. Many considered her experience a valuable lesson, particularly for young women who may be tempted to use diabetes medications like Mounjaro and Ozempic as a quick fix for weight loss.